Bococizumab is a remarkable anti-PCSK9 antibody effectively developed to combat hypercholesterolemia. Such therapeutic agent functions through the PCSK9 protein, a critical regulator of cholesterol levels. By blocking https://www.targetmol.com/compound/bococizumab